SBI Securities Co. Ltd. Has $39,000 Stake in Seres Therapeutics, Inc. $MCRB

SBI Securities Co. Ltd. trimmed its position in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB - Free Report) by 95.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,482 shares of the biotechnology company's stock after selling 66,182 shares during the period. SBI Securities Co. Ltd.'s holdings in Seres Therapeutics were worth $39,000 as of its most recent SEC filing.Separately, Goldman Sachs Group Inc. boosted its stake in Seres Therapeutics by 40.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 21,679 shares during the period. 59.34% of the stock is currently owned by institutional investors. Get Seres Therapeutics alerts:Seres Therapeutics Trading Up 14.2%MCRB opened at $24.71 on Wednesday. The stock's 50 day simple moving average is $17.86 and its 200-day simple moving average is $14.08. The stock has a market cap of $223.63 million, a PE ratio of -5.48 and a beta of 0.19. Seres Therapeutics, Inc. has a 1 year low of $6.53 and a 1 year high of $25.85. Analysts Set New Price TargetsMCRB has been the subject of a number of research analyst reports. Canaccord Genuity Group upped their price target on Seres Therapeutics from $14.00 to $22.00 and gave the stock a "buy" rating in a report on Wednesday, September 24th. Weiss Ratings reiterated a "sell (d)" rating on shares of Seres Therapeutics in a research note on Monday. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Reduce" and a consensus target price of $14.33.Read Our Latest Report on MCRBSeres Therapeutics Profile (Free Report)Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.Read MoreFive stocks we like better than Seres Therapeutics3 Healthcare Dividend Stocks to BuyWhat’s on the Thanksgiving Table? A Stock Pick for Every CourseGrowth Stocks: What They Are, Examples and How to InvestWhy Home Depot’s Pain Could Be a Long-Term Investor’s Gain3 Monster Growth Stocks to Buy NowQualcomm’s Bulls Are Running Out of Room to Be WrongThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Seres Therapeutics Right Now?Before you consider Seres Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.While Seres Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here